API

Flupirtine (100mg)

Drug classification

Non-opioid analgesic; selective neuronal potassium channel opener (SNEPCO).

Dosage form

Lupirtin Capsule is an oral solid capsule containing flupirtine 100 mg.

API strength per dosage

Dose

Flupirtine 100 mg capsules are typically taken orally by adults 1–3 times daily, as directed. Use in children is not established. Dose adjustments or avoidance are recommended in severe renal or hepatic impairment. Always use the lowest effective dose for the shortest duration due to risk of hepatotoxicity. Regular liver function monitoring is advised.

Mechanism of action

Flupirtine acts as a selective neuronal potassium channel opener (mainly K_v7 channels) and NMDA receptor antagonist. By enhancing K+ currents and inhibiting excitatory neurotransmission, it stabilizes neuronal membrane potential, reduces neuronal excitability, and produces analgesic and muscle relaxant effects without significant opioid or NSAID activity.

Indications

Pain relief

Side effects

Fatigue Dizziness Nausea Dryness in mouth Tremors Heartburn Vomiting Abdominal pain Constipation Loss of appetite Depression Headache Abdominal discomfort Sleep disturbance Increased sweating Restlessness Nervousness Flatulence Diarrhea

Pregnancy category

Flupirtine’s safety in pregnancy is not established; use only if potential benefits justify potential risks to the fetus. Avoid unless clearly necessary.

Precautions

Monitor liver function regularly, avoid in patients with pre-existing liver disease, caution with prolonged use, watch for signs of hepatotoxicity, avoid concomitant hepatotoxic drugs, use caution in elderly, not recommended during pregnancy or breastfeeding, monitor for CNS effects such as dizziness or drowsiness.

Contraindications

Hypersensitivity to flupirtine, severe liver impairment, cholestasis, myasthenia gravis, alcohol abuse, concurrent use of other hepatotoxic drugs, pregnancy, breastfeeding.